Biosyent Stock Performance
| RX Stock | CAD 11.70 0.45 4.00% |
Biosyent has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.37, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biosyent's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biosyent is expected to be smaller as well. Biosyent right now shows a risk of 1.94%. Please confirm Biosyent value at risk, as well as the relationship between the skewness and day median price , to decide if Biosyent will be following its price patterns.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Biosyent are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Biosyent may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Forward Dividend Yield 0.0165 | Payout Ratio 0.2917 | Forward Dividend Rate 0.18 | Dividend Date 2024-12-16 | Ex Dividend Date 2024-09-04 |
1 | Insider Selling BioSyent Inc. Insider Sells 500,000 Shares of Stock - MarketBeat | 09/03/2024 |
2 | Should You Be Adding BioSyent To Your Watchlist Today - Yahoo Finance | 09/26/2024 |
3 | BioSyent Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com | 11/19/2024 |
4 | BioSyent Third Quarter 2024 Earnings Beats Expectations - Simply Wall St | 11/22/2024 |
| Begin Period Cash Flow | 5.3 M |
Biosyent |
Biosyent Relative Risk vs. Return Landscape
If you would invest 1,084 in Biosyent on August 28, 2024 and sell it today you would earn a total of 86.00 from holding Biosyent or generate 7.93% return on investment over 90 days. Biosyent is currently generating 0.1397% in daily expected returns and assumes 1.9419% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Biosyent, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biosyent Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biosyent's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biosyent, and traders can use it to determine the average amount a Biosyent's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0719
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | RX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.94 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Biosyent is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biosyent by adding it to a well-diversified portfolio.
Biosyent Fundamentals Growth
Biosyent Stock prices reflect investors' perceptions of the future prospects and financial health of Biosyent, and Biosyent fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosyent Stock performance.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 119.67 M | ||||
| Shares Outstanding | 11.59 M | ||||
| Price To Earning | 16.61 X | ||||
| Price To Book | 3.63 X | ||||
| Price To Sales | 4.01 X | ||||
| Revenue | 31.59 M | ||||
| Gross Profit | 22.86 M | ||||
| EBITDA | 7.99 M | ||||
| Net Income | 6.46 M | ||||
| Cash And Equivalents | 22.46 M | ||||
| Cash Per Share | 1.59 X | ||||
| Total Debt | 1.22 M | ||||
| Current Ratio | 10.10 X | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | 5.83 M | ||||
| Earnings Per Share | 0.60 X | ||||
| Market Capitalization | 135.65 M | ||||
| Total Asset | 41.53 M | ||||
| Retained Earnings | 27.53 M | ||||
| Working Capital | 30.34 M | ||||
About Biosyent Performance
Evaluating Biosyent's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biosyent has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biosyent has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 359.04 | 376.99 | |
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.21 | 0.22 | |
| Return On Assets | 0.16 | 0.16 | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Biosyent performance evaluation
Checking the ongoing alerts about Biosyent for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biosyent help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biosyent is unlikely to experience financial distress in the next 2 years | |
| About 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: BioSyent Third Quarter 2024 Earnings Beats Expectations - Simply Wall St |
- Analyzing Biosyent's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosyent's stock is overvalued or undervalued compared to its peers.
- Examining Biosyent's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biosyent's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosyent's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biosyent's stock. These opinions can provide insight into Biosyent's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biosyent Stock Analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.